NIH's gene patent applications
Executive Summary
National Institutes of Health expect the U.S. Patent and Trademark Office to issue a decision on NIH's cDNA patent applications by the end of the summer, NIH Office of Technology Transfer Director Reid Adler states in an article in the Aug. 14 issue of Science. Adler says the PTO's initial decision "undoubtedly will argue that the claimed cDNA sequences are unpatentable but will provide minimal policy guidance." NIH has filed applications covering more than 2,700 gene sequences that may be mapped in the human genome project ("The Pink Sheet" April 6, p. 14).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth